The CAPItello-291 clinical trial included adults with locally advanced (inoperable) or metastatic HR-positive, HER2-negative breast cancer.
HER2-negative classification in the CAPItello-291 clinical trial: IHC 0 or IHC 1+ or IHC 2+/ISH-.
HER2=human epidermal growth factor receptor 2; HR=hormone receptor; IHC=immunohistochemistry; ISH=in situ hybridization.
Patients with PIK3CA/AKT1/PTEN-altered tumours (n=289) represented 40.8% of the overall population.1*
40.8% Subgroup with PIK3CA/AKT1/PTEN-altered tumours
Gene alterations among the altered patients:
* In adult patients with PIK3CA or AKT1 activating mutations, or for PTEN alterations after disease progression or recurrence after ≥1 prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor.
Adapted from the NCCN guidelines3
NGS=next-generation sequencing.
ASCO recommends that choices be informed by prior treatments and by routine testing for activating mutations that include PIK3CA, or AKT1, or inactivation of PTEN.2
TEST for PIK3CA/AKT1/PTEN alterations
In patients who meet the following criteria:
HR-positive
HER2-negative
Have locally advanced OR metastatic breast cancer following progression on at least one endocrine-based regimen in the metastatic setting OR recurrence on or within 12 months of completing adjuvant therapy
